Somatostatin receptor subtypes 2 and 5 are associated with better survival in well-differentiated endocrine carcinomas

Vito D. Corleto, Massimo Falconi, Francesco Panzuto, Massimo Milione, Ottavia De Luca, Pasquale Perri, Renato Cannizzaro, Cesare Bordi, Paolo Pederzoli, Aldo Scarpa, Gianfranco Delle Fave

Research output: Contribution to journalArticle

Abstract

The majority of gastroenteropancreatic well-differentiated endocrine carcinomas (WDEC) express somatostatin receptors (SSTR). To correlate the expression of SSTR subtypes by reverse transcriptase-polymerase chain reaction (RT-PCR) with clinicopathological features and survival in a group of WDEC patients, 42 WDEC tissue specimens from 33 patients were analysed. All patients were treated with somatostatin analogues and had a median follow-up period of 45 months (range 6-196). Neither SSTR2 and SSTR5 expression nor Ki-67 level alone correlated with survival. A significantly better survival rate was observed in patients with tumours expressing SSTR2, SSTR5 and Ki-67

Original languageEnglish
Pages (from-to)223-230
Number of pages8
JournalNeuroendocrinology
Volume89
Issue number2
DOIs
Publication statusPublished - Feb 2009

Keywords

  • Somatostatin analogues
  • Somatostatin receptor
  • Survival rate
  • Well-differentiated tumours

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Endocrine and Autonomic Systems
  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'Somatostatin receptor subtypes 2 and 5 are associated with better survival in well-differentiated endocrine carcinomas'. Together they form a unique fingerprint.

  • Cite this